Clinical Research Directory

Inclusion Criteria: 1. Males or Females ≥18 years of age, at screening. 2. Confirmed CPVT diagnosis, based on genetic screening for a known RyR2 mutation and a clinical phenotype consistent with CPVT at screening. 3. The participant can perform an EST during which frequent premature ventricular contraction (PVCs) (≥10 per minute), ventricular bigeminy, or higher-grade VA (equivalent to a VA score ≥2) are identified by the investigator. 4. Stable doses of any anti-arrhythmic medication, except amiodarone, for 4 weeks prior to screening. 5. Adhere to all contraceptive criteria. Exclusion Criteria: 1. Clinically significant structural heart disease, diagnosis of heart failure, or clinically significant coronary artery disease. 2. History of a myocardial infarction, cerebrovascular accident, or transient ischemic attack within 3 months of screening. 3. History of malignancy within the past 5 years at screening (except successfully treated basal cell carcinoma or non-metastatic squamous cell carcinoma of the skin or cervical carcinoma in situ). 4. Female participant that is pregnant or lactating/ breastfeeding, or has plans to do so during the study or within 3 months following last dose of study drug. 5. Use of amiodarone with 3 months prior to screening. NOTE: other protocol defined Inclusion/ Exclusion criteria may apply.